| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
40,010,000 |
| Market
Cap: |
893.82(M) |
| Last
Volume: |
1,008,943 |
Avg
Vol: |
1,006,127 |
| 52
Week Range: |
$12.64 - $30.11 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Cassava Sciences is a clinical-stage biotechnology company. Co. has combined technology with insights in neurobiology to develop solutions for Alzheimer's disease and other neurodegenerative diseases. Co. has two biopharmaceutical assets under development: its primary therapeutic product candidate, called simufilam, is a treatment for Alzheimer's disease; and its primary investigational diagnostic product candidate, called SavaDx, is a way to detect the existence of Alzheimer's disease from a small sample of blood.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
48,477 |
278,477 |
| Total Buy Value |
$0 |
$0 |
$831,428 |
$6,164,449 |
| Total People Bought |
0 |
0 |
2 |
4 |
| Total Buy Transactions |
0 |
0 |
3 |
9 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Barry Richard |
Director |
• • – |
2024-04-23 |
4 |
OE |
$22.00 |
$3,873,870 |
I/I |
176,085 |
469,562 |
|
- |
|
| Kupiec James William |
Chief Medical Officer |
• • – |
2024-04-18 |
4 |
OE |
$22.00 |
$33,000 |
D/D |
1,500 |
4,000 |
|
- |
|
| Schoen Eric |
Chief Financial Officer |
• • – |
2024-04-17 |
4 |
OE |
$22.00 |
$33,000 |
D/D |
1,500 |
21,300 |
|
- |
|
| Robertson Sanford |
Director |
– • – |
2023-08-23 |
4 |
B |
$17.45 |
$523,500 |
D/D |
30,000 |
886,851 |
2.39 |
29% |
|
| Barry Richard |
Director |
– • – |
2023-08-22 |
4 |
B |
$16.65 |
$275,907 |
I/I |
16,571 |
293,477 |
2.1 |
31% |
|
| Barry Richard |
Director |
– • – |
2023-08-21 |
4 |
B |
$16.80 |
$32,021 |
I/I |
1,906 |
276,906 |
2.1 |
36% |
|
| Scannon Patrick J Md Phd |
Director |
– • – |
2023-06-12 |
4 |
OE |
$0.95 |
$950 |
D/D |
1,000 |
1,000 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2023-05-24 |
4 |
D |
$25.25 |
$1,205,006 |
D/D |
(47,723) |
734,279 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2023-05-24 |
4 |
OE |
$16.87 |
$1,204,990 |
D/D |
71,428 |
782,002 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2023-05-24 |
4 |
D |
$25.25 |
$241,011 |
I/I |
(9,545) |
380,852 |
|
- |
|
| Barbier Remi |
President and CEO |
• • – |
2023-05-24 |
4 |
OE |
$16.87 |
$240,988 |
I/I |
14,285 |
390,397 |
|
- |
|
| Robertson Sanford |
Director |
– • – |
2023-05-10 |
4 |
OE |
$16.66 |
$165,170 |
D/D |
9,284 |
856,851 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2023-05-01 |
4 |
A |
$23.34 |
$165,177 |
D/D |
7,077 |
10,617 |
|
- |
|
| Gussin Robert Z |
Director |
– • – |
2023-05-01 |
4 |
OE |
$16.66 |
$165,170 |
D/D |
9,284 |
17,694 |
|
- |
|
| O Donnell Michael J |
Director |
– • – |
2023-03-07 |
4 |
D |
$25.20 |
$129,503 |
D/D |
(5,139) |
6,873 |
|
- |
|
| O Donnell Michael J |
Director |
– • – |
2023-03-07 |
4 |
OE |
$16.66 |
$129,484 |
D/D |
7,142 |
12,012 |
|
- |
|
| Barry Richard |
Director |
– • – |
2023-03-07 |
4 |
B |
$25.76 |
$1,990,630 |
I/I |
77,276 |
275,000 |
2.1 |
-13% |
|
| Barry Richard |
Director |
– • – |
2023-03-06 |
4 |
B |
$26.13 |
$302,193 |
I/I |
11,565 |
197,724 |
2.1 |
-18% |
|
| Friedmann Nadav |
Chief Medical Officer |
• • – |
2022-10-03 |
4 |
OE |
$0.95 |
$8,907 |
D/D |
9,376 |
79,910 |
|
- |
|
| Robertson Sanford |
Director |
– • – |
2022-09-08 |
4 |
OE |
$23.59 |
$66,099 |
D/D |
2,802 |
1,027,567 |
|
- |
|
| Barry Richard |
Director |
– • – |
2022-08-23 |
4 |
B |
$23.79 |
$860,223 |
I/I |
36,159 |
186,159 |
2.1 |
18% |
|
| Kupiec James William |
Chief Clinical Dev. Officer |
• – – |
2022-08-23 |
4 |
B |
$24.44 |
$61,100 |
D/D |
2,500 |
2,500 |
2.74 |
18% |
|
| Schoen Eric |
Chief Financial Officer |
• – – |
2022-08-12 |
4 |
B |
$19.95 |
$49,875 |
D/D |
2,500 |
19,800 |
2.74 |
55% |
|
| Robertson Sanford |
Director |
– • – |
2022-08-12 |
4 |
B |
$20.69 |
$2,069,000 |
D/D |
100,000 |
1,024,765 |
2.39 |
55% |
|
| Barbier Remi |
President and CEO |
• • – |
2022-06-06 |
4 |
D |
$27.93 |
$1,528,330 |
D/D |
(54,720) |
767,717 |
|
- |
|
82 Records found
|
|
Page 1 of 4 |
|
|
0.61 (2.81%) 
